GregK
Moderator emeritus
- Joined
- Jan 29, 2013
- Messages
- 3,295
- Reason
- PALS
- Diagnosis
- 11/2012
- Country
- US
- State
- CO
- City
- Colorado Springs
Story: Radicut® Approved for ALS in Japan | ALS Therapy Development Institute
What is Radicut?
According tot he company, Radicut is a free radical scavenger which works to remove oxygen-containing molecules, which build up in people with ALS and other diseases. This antioxidant approach is thought to provide neuroprotective support to the nervous system, potentially slowing down disease progression or limiting additional damage altogether. However, as with all antioxidants of this type, there are potential off-target effects as well as challenges in ensuring the desired antioxidant affect occurs uniformly in the areas of the body intended for such treatment. In the study, and as approved for use following stroke, ALS patients received 60mg of the compound via intravenous injection daily for two weeks followed by two weeks off. Treeway, a Dutch biotechnology company, announced earlier in 2015 it had begun to reformulate Radicut into an oral medication for further exploration in ALS patients; they were awarded Orphan Drug Designation by the FDA and EU this year as well.
What is Radicut?
According tot he company, Radicut is a free radical scavenger which works to remove oxygen-containing molecules, which build up in people with ALS and other diseases. This antioxidant approach is thought to provide neuroprotective support to the nervous system, potentially slowing down disease progression or limiting additional damage altogether. However, as with all antioxidants of this type, there are potential off-target effects as well as challenges in ensuring the desired antioxidant affect occurs uniformly in the areas of the body intended for such treatment. In the study, and as approved for use following stroke, ALS patients received 60mg of the compound via intravenous injection daily for two weeks followed by two weeks off. Treeway, a Dutch biotechnology company, announced earlier in 2015 it had begun to reformulate Radicut into an oral medication for further exploration in ALS patients; they were awarded Orphan Drug Designation by the FDA and EU this year as well.
